Document Detail


Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
MedLine Citation:
PMID:  19453066     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: Recently, complementary alternative medicine is actively performed for cancer therapy. Superfine dispersed lentinan (beta-1,3-glucan)--an oral effective form--was recently developed and available. We investigated the effectiveness of superfine dispersed lentinan in advanced pancreatic cancer patients in a multi-center study. METHODOLOGY: Twenty-nine patients with unresectable and recurrent pancreatic cancer were enrolled, and adverse events and quality of life scores were assessed. Survival times were evaluated according to results of a 3-year follow-up survey. RESULTS: Although a diarrhea of grade-1 adverse event dependent on the test article (3.4%) was observed, the symptom was remitted without any treatment. This indicates that test article was free of anything harmful. Median survival time was 12.1 months (95% confidence interval: 7.3-25.7 months) in 25 eligible patients. Five (20%) out of 25 patients were alive for 3 years. There was a significant correlation between the quality of life scores after the superfine dispersed lentinan treatment and survival times. CONCLUSIONS: A superfine dispersed lentinan is deemed safe and effective for advanced pancreatic patients' survival and improvement of quality of life. And the assessment of quality of life status after the administration of superfine dispersed lentinan is a promising prognostic predictor.
Authors:
Kyoko Shimizu; Shinya Watanabe; Seiji Watanabe; Kenji Matsuda; Tetsuya Suga; Saburo Nakazawa; Keiko Shiratori
Related Documents :
18097296 - Survival and prognostic factors of unresectable pancreatic cancer.
21633836 - Evaluation of molecular prognostic and predictive factors: an important step towards pe...
15902746 - Recurrent acute pancreatitis and its relative factors.
12720536 - Pitfalls in endosonographic imaging of suspected insulinomas: pancreatic nodules of unk...
24252686 - Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradia...
7900236 - Efficacy of tropisetron (navoban) in controlling emesis induced in children by anti-can...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  56     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:    2009 Jan-Feb
Date Detail:
Created Date:  2009-05-20     Completed Date:  2009-06-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  240-4     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Antineoplastic Agents / administration & dosage,  therapeutic use*
Female
Humans
Japan
Lentinan / administration & dosage,  therapeutic use*
Male
Middle Aged
Pancreatic Neoplasms / drug therapy*
Quality of Life
Survival Rate
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 37339-90-5/Lentinan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surgical treatment of giant liver hemangiomas by enucleation using an ultrasonically activated devic...
Next Document:  Successful embolization of pancreaticoduodenal artery pseudoaneurysm in a patient with common hepati...